URGN Stock Analysis: UroGen Pharma | NASDAQ

Biotechnology | NASDAQ, USA | Market Cap: 1.852m USD | 12M Return: 179.8% | Charts, Fundamentals & Technical Analysis

Zusduri, Jelmyto, RTGel, UGN-103
Total Rating 50
Safety 42
Buy Signal 1.02
Biotechnology
Industry Rotation: +30.9
Market Cap: 1.85B
Avg Turnover: 22.4M
Risk 3d forecast
Volatility66.0%
VaR 5th Pctl9.51%
VaR vs Median-10.1%
Reward TTM
Sharpe Ratio1.81
Rel. Str. IBD97.9
Rel. Str. Peer Group83.3
Character TTM
Beta1.198
Beta Downside0.537
Hurst Exponent0.448
Drawdowns 3y
Max DD82.64%
CAGR/Max DD0.71
CAGR/Mean DD1.78
EPS (Earnings per Share) EPS (Earnings per Share) of URGN over the last years for every Quarter: "2021-06": -1.17, "2021-09": -1.35, "2021-12": -1.27, "2022-03": -1.25, "2022-06": -1.18, "2022-09": -1.13, "2022-12": -1.22, "2023-03": -1.3, "2023-06": -1.03, "2023-09": -0.68, "2023-12": -0.72, "2024-03": -0.97, "2024-06": -0.91, "2024-09": -0.55, "2024-12": -0.8, "2025-03": -0.92, "2025-06": -1.05, "2025-09": -0.69, "2025-12": -0.53, "2026-03": -0.47,
Last SUE: -0.05
Qual. Beats: 0
Revenue Revenue of URGN over the last years for every Quarter: 2021-06: 13.032, 2021-09: 11.351, 2021-12: 16.174, 2022-03: 13.564, 2022-06: 16.604, 2022-09: 16.097, 2022-12: 18.092, 2023-03: 17.192, 2023-06: 21.139, 2023-09: 20.852, 2023-12: 23.53, 2024-03: 18.781, 2024-06: 21.848, 2024-09: 25.204, 2024-12: 24.565, 2025-03: 20.254, 2025-06: 24.215, 2025-09: 27.482, 2025-12: 37.837, 2026-03: 50.959,
Rev. CAGR: 18.80%
Rev. Trend: 90.1%
Last SUE: 3.03
Qual. Beats: 1

Warnings

Negative Equity With Losses: Insolvent Profile
Interest Coverage Ratio Critical
Altman Z'' In Financial Distress Zone
Fakeout

Tailwinds

Supp Ema8
Rs Leader
Idiosyncratic Leader
Tailwind

Seasonality 9.1 years of data

Jan +1.0% 2
Feb -2.7% 26
Mar -4.8% 25
Apr +4.7% 15
May -4.1% 24
Jun +14.5% 42
Jul +3.4% 20
Aug +1.7% 0
Sep -5.9% 40
Oct -0.5% 14
Nov +11.2% 16
Dec -9.6% 17

How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.

Description: URGN UroGen Pharma

UroGen Pharma Ltd. (NASDAQ: URGN) is a U.S.-based biotechnology company founded in 2004 and headquartered in Princeton, New Jersey, focused on developing and commercializing treatments for urothelial and specialty cancers. The company markets Zusduri, a sustained-release mitomycin formulation for non-muscle invasive bladder cancer (NMIBC), and Jelmyto for pyelocalyceal solutions, both built on its proprietary RTGel reverse thermal gelation hydrogel technology that enables localized, prolonged drug delivery. Its clinical pipeline includes UGN-103 and UGN-104 in Phase 3 trials for NMIBC indications, and UGN-301-based combinations in Phase 1 development for high-grade NMIBC.

The company maintains licensing and supply partnerships with Agenus Inc. for urinary tract cancer therapies and medac Gesellschaft für klinische Spezialpräparate m.b.H. to support the development of its Phase 3 candidates. As a small-cap biotech that went public in 2017, UroGen operates in the specialty uro-oncology niche, where its hydrogel-based delivery platform is designed to address limitations of conventional intravesical chemotherapy administration.

Headlines to Watch Out For
  • Zusduri launch accelerates NMIBC revenue growth
  • UGN-103 and UGN-104 Phase 3 trial readouts approach
  • Cash burn persists amid commercial scale-up
Piotroski VR-10 (Strict) 2.0
Net Income: -133.2m TTM > 0 and > 6% of Revenue
FCF/TA: -0.46 > 0.02 and ΔFCF/TA 3.79 > 1.0
NWC/Revenue: 133.0% < 20% (prev 212.4%; Δ -79.47% < -1%)
CFO/TA -0.65 > 3% & CFO -165.7m > Net Income -133.2m
Net Debt/EBITDA: error (EBITDA <= 0)
Current Ratio: 4.69 > 1.5 & < 3
Outstanding Shares: last quarter (50.2m) vs 12m ago 5.82% < -2%
Gross Margin: 89.85% > 18% (prev 89.68%; Δ 0.17% > 0.5%)
Asset Turnover: 56.05% > 50% (prev 37.10%; Δ 18.95% > 0%)
Interest Coverage Ratio: -3.08 > 6 (EBIT TTM -118.3m / Interest Expense TTM 38.5m)
Altman Z'' -11.32
A: 0.74 (Total Current Assets 237.5m - Total Current Liabilities 50.6m) / Total Assets 253.7m
B: -3.88 (Retained Earnings -983.3m / Total Assets 253.7m)
C: -0.47 (EBIT TTM -118.3m / Avg Total Assets 250.7m)
D: -0.33 (Book Value of Equity -124.3m / Total Liabilities 377.9m)
Altman-Z'' = -11.32 = D
Beneish M -1.65
DSRI: 1.85 (Receivables 55.4m/19.6m, Revenue 140.5m/91.9m)
GMI: 1.00 (GM 89.68% / 89.85%)
AQI: 1.48 (AQ_t 0.03 / AQ_t-1 0.02)
SGI: 1.53 (Revenue 140.5m / 91.9m)
TATA: 0.13 (NI -133.2m - CFO -165.7m) / TA 253.7m)
Beneish M = -1.65 (Cap -4..+1) = CCC
What is the price of URGN shares?

As of July 08, 2026, the stock is trading at USD 37.75 with a total of 914,043 shares traded. Over the past week, the price has changed by +4.66%, over one month by +38.53%, over three months by +109.37% and over the past year by +179.84%.

Current recommended Stop Loss: 35.70 (which is 5.4% or 1.2 ATR below the current price).

Is URGN a buy, sell or hold?

UroGen Pharma has received a consensus analysts rating of 4.38. Therefore, it is recommended to buy URGN.

  • StrongBuy: 5
  • Buy: 1
  • Hold: 2
  • Sell: 0
  • StrongSell: 0

What are the forecasts/targets for the URGN price?
Analysts Target Price 37.1 -1.6%
UroGen Pharma (URGN) - Fundamental Data Overview as of 07 July 2026
Market Cap USD = 1.85b (1.85b USD * 1.0 USD.USD)
P/S = 13.185
P/B = 16.2331
Revenue TTM = 140.5m USD
EBIT TTM = -118.3m USD
EBITDA TTM = -115.8m USD
Long Term Debt = 189.5m USD (from longTermDebt, last quarter)
Short Term Debt = 1.92m USD (from shortTermDebt, last quarter)
Debt = 202.7m USD (from shortLongTermDebtTotal, last quarter) + Leases 5.65m
Net Debt = 129.9m USD (calculated: Debt 202.7m - CCE 72.8m)
Enterprise Value = 1.98b USD (1.85b + Debt 202.7m - CCE 72.8m)
Interest Coverage Ratio = -3.08 (Ebit TTM -118.3m / Interest Expense TTM 38.5m)
EV/FCF = -16.88x (Enterprise Value 1.98b / FCF TTM -117.4m)
FCF Yield = -5.92% (FCF TTM -117.4m / Enterprise Value 1.98b)
FCF Margin = -83.59% (FCF TTM -117.4m / Revenue TTM 140.5m)
Net Margin = -94.83% (Net Income TTM -133.2m / Revenue TTM 140.5m)
Gross Margin = 89.85% ((Revenue TTM 140.5m - Cost of Revenue TTM 14.3m) / Revenue TTM)
Gross Margin QoQ = 91.88% (prev 91.31%)
Tobins Q-Ratio = 7.81 (Enterprise Value 1.98b / Total Assets 253.7m)
Interest Expense / Debt = 18.98% (Interest Expense 38.5m / Debt 202.7m)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -93.5m (EBIT -118.3m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 3.50 (Total Current Assets 237.5m / Total Current Liabilities 67.8m)
 Debt / Equity = -1.63 (negative equity) (Debt 202.7m / totalStockholderEquity, last quarter -124.3m)
 Debt / EBITDA = -1.12 (negative EBITDA) (Net Debt 129.9m / EBITDA -115.8m)
 Debt / FCF = -1.11 (negative FCF - burning cash) (Net Debt 129.9m / FCF TTM -117.4m)
 Total Stockholder Equity = -109.6m (last 4 quarters mean from totalStockholderEquity)
RoA = -53.15% (Net Income -133.2m / Total Assets 253.7m)
 RoE = 121.5% (negative equity) (Net Income TTM -133.2m / Total Stockholder Equity -109.6m)
 RoCE = -148.1% (out of range, set to none) (EBIT -118.3m / Capital Employed (Equity -109.6m + L.T.Debt 189.5m))
 RoIC = -47.23% (negative operating profit) (NOPAT -93.5m / Invested Capital 197.9m)
 WACC = 10.67% (E(1.85b)/V(2.06b) * Re(10.20%) + D(202.7m)/V(2.06b) * Rd(18.98%) * (1-Tc(0.21)))
Discount Rate = 10.20% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 95.56 | Cagr: 15.69%
 [DCF] Fair Price = unknown (Cash Flow -117.4m)
 EPS Correlation: N/A | EPS CAGR: N/A | SUE: -0.05 | # QB: 0
Revenue Correlation: 90.13 | Revenue CAGR: 18.80% | SUE: 3.03 | # QB: 1
EPS current Quarter (2026-06-30): EPS=-0.29 | Chg30d=+3.29% | Revisions=+25% | Analysts=8
EPS next Quarter (2026-09-30): EPS=-0.10 | Chg30d=+15.56% | Revisions=+44% | Analysts=8
EPS current Year (2026-12-31): EPS=-0.84 | Chg30d=+6.63% | Revisions=+25% | GrowthEPS=+73.5% | GrowthRev=+145.2%
EPS next Year (2027-12-31): EPS=1.23 | Chg30d=+0.10% | Revisions=+10% | GrowthEPS=+245.6% | GrowthRev=+55.9%
[Analyst] Revisions Ratio: +32% (up=21, down=10)